Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Cancer chemo-immunotherapy: time will tell.

Cancer immunology research·2026

Same author

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry.

Blood immunology & cellular therapy·2026

Same author

RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma.

Cancer cell·2026

Same author

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

JCO precision oncology·2026

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.

Tony Kiat Hon Lim¹, Ferdinandos Skoulidis², Keith M Kerr³

¹Division of Pathology, Singapore General Hospital, Singapore.

Lung Cancer (Amsterdam, Netherlands)

|September 8, 2023

Summary

KRAS G12C is a key target in non-small cell lung cancer (NSCLC). Testing for this mutation is crucial for guiding treatment decisions, especially with new targeted therapies available.

Keywords:

Adagrasib Clinical practice Driver oncogene Real-world evidence Sotorasib Targeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Jul 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

KRAS mutations are common in advanced non-squamous non-small cell lung cancer (NSCLC).
KRAS G12C is the most frequent KRAS variant, making it a significant therapeutic target.
The development of KRAS G12C-selective inhibitors has shifted KRAS from a prognostic to a predictive biomarker.

Purpose of the Study:

To review the evolving role of KRAS G12C in advanced NSCLC.
To discuss KRAS G12C biology, prevalence, co-mutations, and molecular testing strategies.
To highlight the clinical relevance of KRAS G12C testing for treatment decisions.

Main Methods:

Literature review of KRAS G12C in advanced NSCLC.
Analysis of real-world prevalence data across different geographic regions.
Examination of clinical data on KRAS G12C co-mutations (STK11, KEAP1, TP53).

Main Results:

Significant geographic variations in KRAS G12C prevalence were observed.
KRAS G12C-mutant NSCLC frequently co-occurs with STK11, KEAP1, and TP53 mutations.
Sotorasib and adagrasib are approved for second-line treatment, emphasizing early testing.

Conclusions:

KRAS G12C testing should be integrated into routine biomarker assessment before first-line therapy.
Next-generation sequencing is recommended for comprehensive biomarker analysis.
Molecular testing results are essential for guiding treatment strategies in KRAS G12C-mutated NSCLC.